Verastem, Inc.
Verastem, Inc. (VSTM) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · VSTM · as of Jun 8, 2026
Key Statistics
Explore Verastem, Inc. Data
vstm stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 19 · Buy rate: 73.7%
The VSTM analyst consensus is Buy, based on ratings from 19 Wall Street analysts over the past 3 months. The average 12-month price target is $18.25, representing +397.28% upside from the current price of $3.67.
Competitors & Peers
vstm competitorsVSTM
ABSI
CRVS
FDMT
GOSS
KALVStock Performance
Full HistoryAbout Verastem, Inc.
Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-676…
what is verastem, inc. · vstm stock overview · verastem, inc. company profile · who is verastem, inc. ceo · vstm NASDAQ · verastem, inc. headquarters · verastem, inc. business segments
About Stock Overview & Key Data
Verastem, Inc. (VSTM) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jan 27, 2012. As of the latest trading session, VSTM stock price is $3.67, with a market capitalization of $254.4M. The stock has returned -39.93% over the past 12 months and -52.46% year-to-date.
According to 19 Wall Street analysts, the consensus rating for Verastem, Inc. stock is Buy, with an average 12-month price target of $18.25. In fiscal year 2025, Verastem, Inc. reported revenue of $30.9M and net income of -$209.5M. For detailed data — including Verastem, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Verastem, Inc. (VSTM) stock price is $3.67. The stock is traded on NASDAQ under the ticker symbol VSTM. The 52-week range is $3.58 – $11.25.